Oruka Therapeutics, Inc.

XNASHealth care

Last traded price · USD

$101.41

+0.00%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:50 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $101.41
Volume: —
Day's high: —
Day's low: —

In brief

Oruka Therapeutics, Inc. is a health care company listed on Nasdaq, valued at about $6.71B.
Its shares closed at $101.41 on 4 Nov 2026, up 269.7% over the past year.
From India you can buy ORKA in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Oruka Therapeutics, Inc. (ORKA) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole ORKA share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade ORKA options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: +26.5% (SPY −1.6%, XLV +13.5%). 3 months: +4.3% (SPY −0.4%, XLV +15.5%). 1 year: +269.7% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ORKA, SPY and XLV · as of 4 Nov 2026
7.3 days to cover short interest
6.1M shares were sold short at the 15 Oct 2026 settlement, 9.2% of the 66.2M shares outstanding; covering them would take 7.3 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $101.41 was 15.0% above its 50-day average ($88.16) and 44.4% above its 200-day average ($70.22). It has closed above the 200-day for 310 sessions, since 13 Aug 2025. The 50-day average crossed above the 200-day on 29 Aug 2025, 297 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
RSI(14) at 70.3, 70 or above
The 14-session relative strength index closed at 70.3 on 4 Nov 2026, its 1st session at 70 or above. By convention a reading of 70 or above is called overbought and 30 or below oversold.
Daily closes, split-adjusted; Wilder's 14-session RSI · as of 4 Nov 2026
84% of the way up its 52-week range
Closed at $101.41 on 4 Nov 2026: 12.2% below the 52-week high of $115.52 (19 Aug 2026) and 301.9% above the low of $25.23 (5 Jan 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+26.5%

6 months+45.3%

1 year+269.7%

5 years—

Newswire

About

Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.

Website

Notable moves

June 22, 2026
+18.03%
March 13, 2026
+25.04%
September 29, 2025
+26.91%

Newswire

About

Website

Notable moves

June 22, 2026
+18.03%
March 13, 2026
+25.04%
September 29, 2025
+26.91%

Oruka Therapeutics, Inc.

XNASHealth care

Last traded price · USD

$101.41

+0.00%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 15:50 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $101.41
Volume: —
Day's high: —
Day's low: —

In brief

Oruka Therapeutics, Inc. is a health care company listed on Nasdaq, valued at about $6.71B.
Its shares closed at $101.41 on 4 Nov 2026, up 269.7% over the past year.
From India you can buy ORKA in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Oruka Therapeutics, Inc. (ORKA) shares from India?

Do I need the price of a whole ORKA share to invest?

How much can I invest in US stocks in a year?

Can I trade ORKA options or futures?

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: +26.5% (SPY −1.6%, XLV +13.5%). 3 months: +4.3% (SPY −0.4%, XLV +15.5%). 1 year: +269.7% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ORKA, SPY and XLV · as of 4 Nov 2026
7.3 days to cover short interest
6.1M shares were sold short at the 15 Oct 2026 settlement, 9.2% of the 66.2M shares outstanding; covering them would take 7.3 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $101.41 was 15.0% above its 50-day average ($88.16) and 44.4% above its 200-day average ($70.22). It has closed above the 200-day for 310 sessions, since 13 Aug 2025. The 50-day average crossed above the 200-day on 29 Aug 2025, 297 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
RSI(14) at 70.3, 70 or above
The 14-session relative strength index closed at 70.3 on 4 Nov 2026, its 1st session at 70 or above. By convention a reading of 70 or above is called overbought and 30 or below oversold.
Daily closes, split-adjusted; Wilder's 14-session RSI · as of 4 Nov 2026
84% of the way up its 52-week range
Closed at $101.41 on 4 Nov 2026: 12.2% below the 52-week high of $115.52 (19 Aug 2026) and 301.9% above the low of $25.23 (5 Jan 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month+26.5%

6 months+45.3%

1 year+269.7%

5 years—

Newswire

About

Website

Notable moves

June 22, 2026
+18.03%
March 13, 2026
+25.04%
September 29, 2025
+26.91%

Newswire

About

Website

Notable moves

June 22, 2026
+18.03%
March 13, 2026
+25.04%
September 29, 2025
+26.91%

Oruka Therapeutics, Inc.

Oruka Therapeutics, Inc. in brief

Ahead of SPY and its sector fund XLV over 1 year

7.3 days to cover short interest

Above its 50- and 200-day averages

RSI(14) at 70.3, 70 or above

84% of the way up its 52-week range

Oruka Therapeutics, Inc.

Oruka Therapeutics, Inc. in brief

Ahead of SPY and its sector fund XLV over 1 year

7.3 days to cover short interest

Above its 50- and 200-day averages

RSI(14) at 70.3, 70 or above

84% of the way up its 52-week range